Ipsen Acquires Global Rights to Mesdopetam

Ipsen Acquires Global Rights to Mesdopetam

299917

Ipsen Acquires Global Rights to Mesdopetam

Ipsen has entered into an exclusive worldwide licensing agreement with Integrative Research Laboratories (IRLAB) to develop and commercialize mesdopetam, an experimental therapy for reducing levodopa-induced dyskinesia, or involuntary movements, in people with Parkinson’s disease. “We are excited to enter this licensing agreement with IRLAB. By working in partnership, we aim to bring investigational mesdopetam to people living with Parkinson’s disease experiencing levodopa-induced dyskinesia,” Howard Mayer, MD, executive vice-president and head of research and development at Ipsen, said in a…

You must be logged in to read/download the full post.